Video

CLL: Venetoclax in the R/R Setting

Author(s):

William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine

Experts in chronic lymphocytic leukemia (CLL) discuss retreating patients with venetoclax.

Related Videos
John M. Burke, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
David C. Fisher, MD
David C. Fisher, MD
Nitin Jain, MD
Kathleen A. Dorritie, MD
Alexey Danilov, MD, PhD
Related Content
Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 19th 2024

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Chronic Lymphocytic Leukemia | stock.adobe.com
December 10th 2024

Pirtobrutinib Improves PFS in Previously Treated CLL/SLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 10th 2024

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

B-Cell Malignancies
December 9th 2024

Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies